This is the largest worldwide action aimed at screening for malignant skin neoplasms, surpassing the initiatives of the European community. 2 In addition to actions associated with population health ...

The researchers estimated the 30-year cumulative incidence of any cutaneous malignant neoplasm to be 27.4%. Patients who have undergone blood or marrow transplantation (BMT) are at significant ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase II for Malignant Neoplasms. According to GlobalData, Phase II drugs for Malignant Neoplasms does not have sufficient ...

Head and neck neoplasms have a poor prognosis because of their late diagnosis. Finding a biomarker to detect these tumors in an early phase could improve the prognosis and survival rate. This ...